Raynaud phenomenon and systemic scleroderma;RAYNAUD-PHANOMEN UND SKLERODERMIE

Hautarzt

Volumn 47, Issue 5, 1996, Pages 336-340

  Haustein, U F ^a,b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b NONE

Author keywords

neuropeptides; Raynaud phenomenon; systemic sclerosis; vascular tone

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; VASODILATOR AGENT;

HUMAN; RAYNAUD PHENOMENON; REVIEW; SYSTEMIC SCLEROSIS; DRUG EFFECT; PATHOPHYSIOLOGY; PHYSIOLOGY; THROMBOCYTE ACTIVATION; VASCULAR ENDOTHELIUM; VASOCONSTRICTION; VASODILATATION;

CALCITONIN GENE-RELATED PEPTIDE; ENDOTHELIUM, VASCULAR; HUMANS; PLATELET ACTIVATION; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC; VASOCONSTRICTION; VASODILATION; VASODILATOR AGENTS;

EID: 0029890315     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001050050427     Document Type: Review

References (61)

1. Allen E. Brown GE (1932) Raynaud's disease: a critical review of minimal requisites for diagnosis. Am J Med Sci 138: 187-200
2. Bedarida GV, Kim D, Blaschke TF, Hoffmann BB (1993) Venodilation in Raynauds Disease. Lancet 342: 1451-1454
3. Belch JJ (1990) Raynaud's phenomenon. Curr Opin Rheumatol 2: 937-941
4. Belch JJ, McLaren M, Anderson J, Lowe GD, Sturrock RD, Capell HA, Forbes CD (1985) Increased prostacyclin metabolites and decreased red cell deformability in patients with systemic sclerosis and Raynaud's Syndrome. Prostaglandins Leukotriens 17: 1-9
5. Bunker CB, Reavlely C, O'Shaughnessy DL, Dowd PM (1993) Calcitonin gene related peptide in treatment of severe peripheral vascular insufficiency in Raynaud's phenomenon. Lancet 342: 80-82
6. Chevendra V, Weaver LC (1992) Distribution of neuropeptide Y, vasoactive intestinal peptide and somatostatin in populations of postganglionic neurons innervating the rat kidney, spleen and intestine. Neuroscience 50: 727-743
7. Church MK, Lowman MA, Robinson C, Holgate ST, Benyon RC (1989) Interaction of neuropeptides with human mast cells. Int Arch Allergy Appl Immunol 88: 70-78
8. Coffman JD (1989) Raynaud's Phenomenon. Oxford University Press, Oxford
9. Dessein P, Joffe B, Metz R, Millar D, Lawson M, Stenwicks A (1992) Autonomic dysfunction in systemic sclerosis: sympathetic overactivity and instability. Am J Med 93: 143-150
10. Dowd PM, Bunker CB, Bull HA, Foreman JC. Terenghi C, Springall DR, Polak JM (1990) Raynaud's phenomenon, calcitonin gene-related peptide. endothelin, and cutaneous vasculature (letter). Lancet 336: 1014
11. Eton T, Igarashi A, Iozumi K, Ishibashi Y, Takehara K (1990) The effects of scleroderma sera on endothelial cell survival in vitro. Arch Dermatol Res 282: 515-519
12. Fleischmajer R, Perlish JS, Shaw KV, Pirozzi DJ (1976) Skin capillary changes in early systemic scleroderma. Arch Dermatol 112: 1553-1557
13. Foreman JC (1988) The skin as an organ for the study of the pharmacology of neuropeptides. Skin Pharmacol 1: 77-83
14. Foreman JC, Jordan CC (1984) Neurogenic inflammation. Trends Pharmacol Sci 91: 116
15. Freemom AJ, Hoyland J, Fielding P, Hodson N, Jayson MIV (1992) Studies of the microvascular endothelium in uninvolved skin of patients with systemic sclerosis: direct evidence for a generalized microangiopathy. Br J Dermatol 126: 561-568
16. Furchgott RF, Vanhoutte P (1989) Endothelium-derived relaxing and contracting factors. FASEB J 3: 2007-2018
17. Furchgott R, Zawadzki J (1980) Obligatory role of endothelial cells in relaxation of arterial smooth muscle by acetylcholine. Nature 288: 373-376
18. Geirsson AJ, Jonsson GS, Asgeirsdotir LP (1994) Funktional study of the dermal microcirculation in systemic sclerosis. Scand J Rheumatol 23: 73-76
19. Goldermann R, Kübler S, Schulte-Huermann P, Goerz G (1994) Das Raynaud-Phänomen (RP). Z Hautkr 69: 585-589
20. Haustein U-F (1976) Das Gefäßsystem bei der progressiven Sklerodermie. Dermatol Monatschr 162: 721-725
21. Haustein U-F, Weber B, Seikowski K (1995) Substanz P und vasoaktives intestinales Peptid bei Patienten mit progressiver Sklerodermie. Hautarzt 46: 102-106
22. Haustein U-F, Scheel H, Siegemund A, Krusche U (1995) Parameter der Gefäß funktion bei idiopathischer und quarzinduzierter progressiver Sklerodermie. Hautarzt 44: 717-722
23. Haustein U-F, Herrmann K (1990) Pathogenetische, diagnostische und therapeutische Gesichtspunkte der progressiven Sklerodermie. Z Klin Med 45: 201-206
24. Hirata Y, Takagi Y, Fukuda Y, Marumo F (1989) Endothelin is a potent mitogen for rat vascular smooth muscle cells. Artherosclerosis 78: 225-228
25. Holzer P (1988) Local effector functions of capsaicin sensitive sensory nerve endings: involvement of tachykinins, CGRP and other neuropeptides. Neuroscience 24: 739-768
26. Hornstein OP, Steffan C, Diepgen TL, Hiller D, Albrecht H-P, Gruschwitz MS (1993) Therapie der progressiven systemischen Sklerodermie mit Calcitonin: Ein 10jähriger Erfahrungsbericht. Z Hautkr 68: 437
27. Hosoi J, Murphy GF, Egan CL, Lerner EA, Grabbe S, Asahina A, Granstein RD (1993) Regulation of Langerhans cell function by nerves containing calcitonin gene-related peptide. Nature 363: 159-163
28. Jancso G, Jancso-Gabor A, Szolcsanyi J (1967) Direct evidence for neurogenic inflammation and its prevention by denervation and by pretreatment with capsaicin. Br J Pharmacol 31: 138-151
29. Jenssen TG, Haukland HH, Burhal PG (1988) Brain-gut peptides in sauna induced hyperthermia. Acta Physiol Scand 132: 519-523
30. Jorizzo JL, Coutes AA, Eady RAJ. Greaves M (1983) Vascular responses of human skin to injection of substance P and mechanism of action. Eur J Pharmacol 87: 67-76
31. Kaada B (1987) Successful treatment of esophageal dysmotility and Raynaud's phenomenon in systemic sclerosis and achalasia by transcutaneous nerve stimulation. Scand J Gastroenterol 22: 1137-1146
32. Kahaleh MB (1991) Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. Arthritis Rheuma 34: 978-983
33. Kahaleh B, Fan P-S, Matucci-Cerinic M, Stefanovic-Racic M, Ignarro L (1993) Study of endothelial dependent relaxation in scleroderma (abstract). Arthritis Rheum 36 [Suppl 9]:S180
34. Kahaleh MB, LeRoy EC (1988) Endothelial injury in scleroderma: a protease mechanism. J Lab Clin Med 101: 553-560
35. Kahaleh MB, Osborn I, LeRoy EC (1982) Elevated levels of circulating platelets aggregates and β-thromboglobulin in scleroderma. Ann Intern Med 96: 610-613
36. Kallenberg CGM (1991) Connective tissue disease in patients presenting with Raynaud's phenomenon alone. Ann Rheum Dis 50: 666-667
37. Klimiuk PS, Taylor L, Baker RD, Jayson MTV (1988) Autonomic neuropathy in systemic sclerosis. Ann Rheum Dis 47: 542-545
38. Knock GA, Terenghi G, Bunker CB, Bull HA, Dowd PM, Polak JM (1993) Characterization of endothelin-binding sites in human skin and their regulation in primary raynaud's phenomenon and systemic sclerosis. J Invest Dermatol 101: 73-78
39. Lewis T, Landis EM (1929) Observations upon the vascular mechanism in acrocyanosis. Heart 15: 7-101
40. Lotz M, Vaughan JH, Carson DA (1989) Effect of neuropeptides on production of inflammatory cytocines by human monocytes. Science 241: 1218-1221
41. Maggi CA (1991) The pharmacology of the effect function of sensory nerves. J Auton Pharmacol 11: 173-208
42. Maricq HR, Diat F, Weinreich MC, Maricq JG (1994) Digital pressure responses to cooling in patients with suspected early vs definitie scleroderma (systemic sclerosis) vs Primary Raynaud's Phenomenon. J Rheumatol 21: 1472-1476
43. Maricq HR, LeRoy EC, D'Angelo WA (1980) Diagnostic potential of in vivo capillary microscopy in scleroderma and related disorders. Arthritis Rheum 23: 183-189
44. Mattucci-Cerinic M (1993) Sensory neuropeptides and the rheumatic diseases. Rheum Dis Clin North Am 19: 975-991
45. Nilsson J, Euler von AM, Dalsgaard CJ (1985) Stimulation of connective tissue cell growth by substance P and substance K. Nature 315: 61-63
46. Norton WL, Hurd ER, Lewis DC, Ziff M (1968) Evidence of microvascular injury in scleroderma and systemic lupus erythematosis: quantitative study of the microvascuiar bed. J Lab Clin Med 71: 919-933
47. Pawlowski A (1963) The nerve network of the skin in diffuse scleroderma and clinically similar condition. Arch Dermatol 88: 868-873
48. Payan DG, Brewster DR, Goetz EJ (1983) Specific stimulation of human T lymphocytes by substance P. J Immunol 131: 1613-1615
49. Prescott RJ, Freemont AJ, Jones CJP, Hoyland J, Fielding P (1992) Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 166: 255-263
50. Priollet P, Vayssairat M, Housset E (1987) How to classify Raynaud's phenomenon: long-term follow-up study of 73 cases. Am J Med 83: 494-498
51. Raynaud M (1888) On asphyxia and symmetrical gangrene of the extremities 1862 and new researches on the nature and treatment of local asphyxia of the extremities 1874. Translated by T Barlow. New Sydenham Society, London
52. Rosenbaum J, Pottinger BE, Woo P, Black CM, Loizou S, Byron MA, Pearson JD (1988) Measurement and characterisation of circulating anti-endothelial cell IgG in connective tissue diseases. Clin Exp Immunol 72: 450-456
53. Rustin MHA, Bull HA, Ziegler V, Mehlhorn J, Haustein UF, Maddison PJ, James J, Dowd PM (1990) Silica-associated systemic sclerosis is clinically, serologically and immunologically indistinguish-able from idiopthic systemic sclerosis. Br J Dermatol 123: 725-734
54. Schady W, Sheard A, Hassell A, Holt L, Jayson MI, Klimiuk P (1991) Peripheral nerve dysfunction in scleroderma. Q J Med 80: 661
55. Terenghi G, Bunker CB, Liu Y, Springall DR, Cowen T, Dowd PM, Polak JM (1991) Image analysis quantification of peptide-immunoreactive nerves in the skin of patients with Raynaud's phenomenon and systemic sclerosis. J Pathol 164: 245
56. Vallance P, Collier J, Moncada S (1989) Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 2: 997-1000
57. Wallengren J, Ekman R, Sundler F (1987) Occurrence and distribution of neuropeptides in the human skin. Acta Dermatol Venereol (Stockh) 67: 185-192
58. Widdicombe JG (1991) Neural control of airway vasculature and edema. Am Rev Respir Dis 143: 18-21
59. Wigley FM (1993) Raynaud's phenomenon. Curr Opin Rheumatol 5: 773-784
60. Youssef P, Engiert H, Bertoucj J (1993) Large vessel occlusive disease associated with CREST syndrome and scleroderma. Ann Rheum Dis 52: 464-466
61. Zamora MR, O'Brien RF, Rutherford RB, Weil JV (1990) Serum endothelin-1 contrations and cold provocation in primary Raynaud's phenomenon. Lancet 336: 1144-1147